141 related articles for article (PubMed ID: 32447931)
21. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
22. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
23. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
24. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.
van Dussen L; Biegstraaten M; Hollak CE; Dijkgraaf MG
Orphanet J Rare Dis; 2014 Apr; 9():51. PubMed ID: 24731506
[TBL] [Abstract][Full Text] [Related]
26. Gaucher disease.
Nagral A
J Clin Exp Hepatol; 2014 Mar; 4(1):37-50. PubMed ID: 25755533
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease.
Nascimbeni F; Cassinerio E; Dalla Salda A; Motta I; Bursi S; Donatiello S; Spina V; Cappellini MD; Carubbi F
Mol Genet Metab; 2018 Sep; 125(1-2):64-72. PubMed ID: 30115580
[TBL] [Abstract][Full Text] [Related]
28. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
[TBL] [Abstract][Full Text] [Related]
29. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy.
Weinreb NJ; Lee RE
Crit Rev Oncog; 2013; 18(3):177-95. PubMed ID: 23510063
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
31. A new framework for evaluating the health impacts of treatment for Gaucher disease type 1.
Ganz ML; Stern S; Ward A; Nalysnyk L; Selzer M; Hamed A; Weinreb N
Orphanet J Rare Dis; 2017 Feb; 12(1):38. PubMed ID: 28219443
[TBL] [Abstract][Full Text] [Related]
32. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.
van Dussen L; Biegstraaten M; Dijkgraaf MG; Hollak CE
Orphanet J Rare Dis; 2014 Jul; 9():112. PubMed ID: 25056340
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy.
Lo SM; Liu J; Chen F; Pastores GM; Knowles J; Boxer M; Aleck K; Mistry PK
J Inherit Metab Dis; 2011 Jun; 34(3):643-50. PubMed ID: 21445609
[TBL] [Abstract][Full Text] [Related]
34. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
35. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.
Piran S; Amato D
J Inherit Metab Dis; 2010 Jun; 33(3):271-9. PubMed ID: 20336376
[TBL] [Abstract][Full Text] [Related]
36. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
37. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
38. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
Hsu CC; Chien YH; Lai MY; Hwu WL
J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
[TBL] [Abstract][Full Text] [Related]
39. Type I Gaucher disease (GDI) in three siblings: enzyme replacement treatment (ERT) required.
Gucev ZS; Tasic V; Pop-Jordanova N; Kirovski I; Stomnaroska O; Martinova M; Jancevska A; Kremensky I; Sinigerska I
Prilozi; 2009 Jul; 30(1):233-40. PubMed ID: 19736544
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
Weinreb NJ; Finegold DN; Feingold E; Zeng Z; Rosenbloom BE; Shankar SP; Amato D
Orphanet J Rare Dis; 2015 May; 10():64. PubMed ID: 25994334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
